SlideShare a Scribd company logo
1 of 25
Myanmar Pharmaceutical
       Market
      An over View
Myanmar Health Care Information

Myanmar Overview
                                           • Mandalay
                                           • Meikhtila
                                           • Pakokku
                                           • Monywa
 • Yangon                                  • Moegok
 • Mawlamyine                              • Myitkyinar
 • Bago                                    • Taunggyi
 • Pyay                                    • Lashio
 • Pathein
 • Myeik
 • Sittway
 • Taungu
Myanmar Pharmaceutical Market Overview

•   Estimated pharmaceutical market size is about US$ 100-120 millions CIF value.

•   Indian Pharma Companies are about 35 % of the total market.

•   Leading Indian players are Ranbaxy, Cipla, Dr.Reddy’s…..etc.

•   Multi National Companies are less active directly.

•   Two major cities (Ygn & Mdy) contribute 60 % of total sales of Pharma Market.

•   District areas contribute remaining 40%

•   Growing awareness of Health care & modern life style in Major cities are increasing.

•   Number of Private Hospitals & pharmacies are increasing as well.

•   Some international hospitals like Bumrungrad Hospital, Bangkok Hospital are coming up.

•   Prescription drugs can be sold in open market.
Myanmar Pharmaceutical Market


 YANGON, Mar 30 (Xinhua): Pharmaceutical products from Asian countries are
dominating Myanmar's consumers market with India standing as the country's largest
pharmaceutical products importing country, the local weekly Flower News reported
today.

Accounting for 40 per cent of Myanmar's pharmaceuticals import, India is followed by
Bangladesh, China, Thailand, Indonesia, Pakistan and Vietnam.

According to the statistics of the Ministry of Commerce, Myanmar imported over
5,000 categories of pharmaceutical products annually.

In the fiscal year 2007-08, Myanmar imported pharmaceutical products worth of
115.56 million U.S. dollars, an increase of 15.5 per cent from 2006-07, earlier
statistics shows.

Meanwhile, Myanmar's largest and most modern pharmaceutical factory in the
northern city of Pyin Oo Lwin was established in December 2007 producing 162 kinds
of medicines.
With the aim of reducing import-substitute medicines, the Pyin Oo Lwin
Pharmaceutical Factory under the Ministry of Industry-1, produce high-quality modern
medicines such as tablet, capsule, intramuscular, intravenous, lotion and powder.

There has been some five other pharmaceutical factories in Myanmar, including two
special ones, respectively located in Yangon, Sagaing and Inyaung.

These factories are producing medicines that supply 40 per cent of the domestic
market.

Moreover, a famous Myanmar private pharmaceutical company, FAME, will produce
seasonal medicines for Japan and South Korea as proposed by the two countries.

FAME is known as the first private pharmaceutical factory in Myanmar whose
products meet the stringent Good Manufacturing Practices (GMP) standards set by
the World Health Organisation ( WHO).

The company produces 45 different kinds of Myanmar traditional herbal medicines
and its products were exported to countries or regions such as Malaysia, Singapore,
Thailand, Taiwan, South Korea , Germany and Japan
Myanmar Pharmaceutical Market 2011-12
                                     Market Share
                              Therapeutical Segment wise


Sr.No   Therapeutical Segement Market share
 1      Anti Infective             35%
 2      Vitamins                   30%                              Anti Infective
                                                         2%
 3      Analgesics                 11%             2%
                                                  3%
                                                     3%4%           Vitamins
                                                                    Analgesics
                                                              35%
 4      Cardiovascular             10%          10%                 Cardiovascular
                                                                    Gastrointestinal
 5      Gastrointestinal           3%           11%                 Endocardinal
                                                                    Respiratory
 6      Endocardinal               2%                   30%         CNS
                                                                    Others
 7      Respiratory                3%
 8      CNS                        4%
 9      Others                     2%
Share of Export Countries
                                 in
                 Myanmar Pharmaceutical Market 2011-12

                                                        Share of Countries
Sr.No   Countries        Share
 1      India            33%            Others

 2      Thailand         15%            France

 3      Phillipines       6%               USA

 4      UK                5%             China

 5      Indonesia         4%             Korea

                                     Myanmar
 6      Myanmar           4%                                                       Share

                                     Indonesia
 7      Korea             4%
                                            UK
 8      China             4%
                                     Phillipines
 9      USA               3%
                                      Thailand
 10     France            3%              India
 11     Others           18%                       0%   10%   20%   30%      40%
Hospital Data

•   Medical & Health Facilities & Personnel     •     Doctors in Myanmar


                                                    1 No of Drs in State service      6331
    1 Approximate Specialist Hospital    35
                                                    2 No of Drs in Private practice   11145
    2 Hospital with specialist service   29             Total                         17476
    3 Hospital above 25 bedded           302
         Total                           366
UNION OF MYANMAR
                                          Ministry of Health
                                         Department of Health

                                      Food and Drug Administration
                                   Office No(47),Nay Pyi Taw, Myanmar




Registration Procedure
•   Toapply name registration for assessment fees ( It will take 10 days or 14 days )
•   After getting assessment fees documents from FDA, to remit assessment fees on
    Monday and Wednesday only at FDA.
    - Monday ( variation fees, assessment fees, registration fees )
    - Wednesday ( assessment fees, registration fees )
•   After remitting the assessment fees, to apply FDA permit ( It will take 10 days )
•   After getting FDA permit, to apply FOC Trade permit at Airport Trade Office. ( It will
    take 2-3 days only )
    - Need to apply Trade permit if the weight of samples is too much. (or) if the products
    too much for samples dispatching.
•   After getting FDA permit and Trade permit, to inform to dispatch the samples and to
    submit at FDA.
•   After submitting the samples, to submit the dossiers.
• - For dossier submission,
  - Need to take number upto 9:30 am on Tuesday for renwal and on
  Thursday for new product.
  - Firstly FDA accept the dossiers without checking details and
  unlimited dossier qty.
  - Up to 3 pm only. ( renewal on Tuesday/new on Thursday )
  - Then, after two weeks, FDA issue the preview for the complete
  dossier, and return back the incomplete dossier to whom concern.
  Time is from 3 pm to 4:30 pm.
• Next, two weeks, can pay lab test fees.
• After paid lab test fees, our product is under registration process and
  have to follow up and have to wait for approval.
• After getting approval, to pay registration fees.
• After two months, we will get DRC.
  - After getting DRC, to apply attachment for DIAC. ( It will take 3
  weeks. )
Import Procedure for Medicines in Myanmar
•   STEP I
•   Application of import price confirmation at MPMEEA ( Myanmar Pharmaceutical & Medical Equipment Entrepreneurs'
    Association )
•   Documents required:
•   Data format form issued by MPMEEA for application
•   Usage of Medicine
•   Respective Original Drug Registration Certificate ( DRC ) issued by Myanmar Food and Drug Board of Authority
•   Original Drug Importation Approval Certificate ( DIAC ) issued by Myanmar Food and Drug Board of Authority of import
    applied company
•   Membership Certificate of MPMEEA
•   Database CD contained all import data of respective item ( soft & hard copies )
•   Process running time at MPMEEA:
    Two days if all documents are correct

•   STEP II
•   Date entry process at import section ( Yangon ) under Ministry of Commerce
•   Documents required:
•   Import application document
•   Self commitment for import price confirmation
•   Usage of Medicine
•   Proforma Invoice
•   Sale Contract
•   Import price confirmation endorsed by MPMEEA
•   Market price record for respective medicine
•   Process running time at import section ( Yangon ) :
    Two days if all documents are correct.
•   STEP - III

•   Bank Credit inspection and online data entry at import section ( Yangon ) under Ministry of
    Commerce
•   Documents required for Bank credit inspection :
•   Application letter
•   Original bank credit slip and two copies
•   Bank original passport and one copy
•   Process running time for bank credit inspection:
    One day if all documents are correct.
•   Documents required for online data entry:
•   Copy of proforma invoice
•   Copy of Sale Contract
•   Copy of Certificate of Exporter/Importer Registration issued by Directorate of Trade, Ministry
    of Commerce
•   Usage of medicine
•   Company distribution price for respective medicine
•   Bank credit slip
•   Self commitment for import price confirmation
•   Custom H S Code for Section One ( Medicine )
•   Process running time for online data entry:
    One day if all documents are correct.
•   STEP IV
•   Final import application at import section under Ministry of Commerce in
    Naypyitaw ( capital of Union of Myanmar )
•   Documents required:
•   Import application with company letter head
•   Online data entry record ( Original )
•   Proforma invoice
•   Sale Contract
•   Bank credit slip
•   Usage of medicine
•   Company distribution price for respective medicine
•   BOD list of import company
•   Import price confirmation endorsed by MPMEEA
•   Copy of Certificate of Exporter/Importer Registration issued by Directorate of
    Trade, Ministry of Commerce
•   Respective Drug Registration Certificate ( DRC ) issued by Myanmar Food and Drug
    Board of Authority
•   Drug Importation Approval Certificate ( DIAC ) issued by Myanmar Food and Drug
    Board of Authority of import applied company
•   Data Format Chart of Export Income
•   Process running time:
    Two weeks if all documents are correct.
•   STEP V
•   L/C opening procedure at Myanma Foreign Trade Bank, Yangon ( MFTB ) or
    Myanma Investment and Commercial Bank, Yangon ( MICB )
•   Documents required:
    Original import licence issued by Ministry of Commerce
•   L/C data entry form issued by banks
•   copy of Proforma invoice
•   Cheque ( 2 sets )
•   Bank passport ( 2 copies )
•   Import license original and one copy
•   Two copies of Proforma Invoice
•   Process running time: Three days if all documents are correct.
Economical Indicators of Myanmar Market




Myanmar Population Growth Rate, Birth Rate, Death Rate, Net Migration Rate

       Myanmar Age Structure, Median Age, Gender and Urbanization

 Myanmar Life Expectancy Rate, Infant Mortality Rate and Total Fertility Rate

        Myanmar HIV, AIDS and Other Major Infectious Disease Rates

         Myanmar Industries and Industrial Growth Production Rate
Economical Indicators of Myanmar

•   Myanmar Population Growth Rate, Birth Rate, Death Rate, Net Migration Rate :
•   Population growth rate: 1.084%
•   Birth rate: 19.31 births/1,000 population
•   Death rate: 8.16 deaths/1,000 population
•   Net migration rate: -0.31 migrant(s)/1,000 population




•   Myanmar Age Structure, Median Age, Gender and Urbanization :
•   Age structure: 0-14 years: 27.5% (male 7,560,859/female 7,278,652)
•   5-64 years: 67.5% (male 18,099,707/female 18,342,696)
•   65 years and over: 5% (male 1,184,291/female 1,533,599)
•   Median Age: total: 26.9 years male: 26.3 years female: 27.5 years
•   Sex ratio: at birth: 1.06 male(s)/female under 15 years: 1.04 male(s)/female
•   15-64 years: 0.99 male(s)/female 65 years and over: 0.77 male(s)/female
•   total population: 0.99 male(s)/female
Economical Indicators of Myanmar

•   Myanmar Life Expectancy Rate, Infant Mortality Rate and Total Fertility Rate :
•   Life expectancy at birth: total population: 64.88 years male: 62.57 years female: 67.33 years
•   Infant mortality rate: total: 49.23 deaths/1,000 live births male: 56.16 deaths/1,000 live births
    female: 41.88 deaths/1,000 live births
•   Total fertility rate: 2.26 children born/woman



•   Myanmar HIV, AIDS and Other Major Infectious Disease Rates :
•   HIV/AIDS - adult prevalence rate: 0.6%
•   HIV/AIDS - people living with HIV/AIDS: 240,000
•   HIV/AIDS - deaths: 18,000
•   Major infectious diseases: degree of risk:
•   very high food or waterborne diseases:
•   bacterial and protozoal diarrhea, hepatitis A, and typhoid fever vectorborne diseases:
•   dengue fever and malaria water contact disease: leptospirosis animal contact disease: rabies
    note: highly pathogenic H5N1 avian influenza has been identified in this country;
•   it poses a negligible risk with extremely rare cases possible among US citizens who have close
    contact with birds
Economical Indicators of Myanmar

•   Myanmar Industries and Industrial Growth Production Rate :
•   Industries: agricultural processing; wood and wood products;
•    copper, tin, tungsten, iron; cement, construction materials;
•   pharmaceuticals; fertilizer; oil and natural gas; garments,
•    jade and gems
•   Industrial production growth rate: 4.3%
Economical Indicator Forecast up to
   2016 for Myanmar Markets
Year 2012              Year 2013            Year 2014              Year 2015                 Year 2016
Sr. No. Economic Indicator Listing for Myanmar                       Indicator Value        Indicator Value          Indicator Value    Indicator Value           Indicator Value
   1 GDP Growth (Constant Prices, National Currency)                 5.50%                  5.67%                         5.68%         5.68%                     5.69%
   2 GDP (Current Prices, National Currency)                         MMK 45,931.80 Billion. MMK 51,820.81        MMK 58,469.01 Billion. MMK 65,974.81 Billion.    MMK 74,449.42 Billion.
                                                                                            Billion.
  3    GDP (Current Prices, US Dollars)                              US$ 53.451 Billion     US$ 55.839 Billion     US$ 58.338 Billion   US$ 60.953 Billion        US$ 63.689 Billion
  4    GDP Deflator                                                  608 (Index, Base Year 649.159 (Index, Base 693.104 (Index, Base 740.023 (Index, Base Year 790.119 (Index, Base Year
                                                                     as per country's      Year as per country's Year as per country's as per country's accounts as per country's accounts =
                                                                     accounts = 100)       accounts = 100)         accounts = 100) = 100)                        100)

   5   GDP Per Capita (Constant Prices, National Currency)           MMK 118,648.72 .       MMK 122,903.20 .       MMK 127,319.28 .     MMK 131,903.40 .          MMK 136,662.25 .
   6   GDP Per Capita (Current Prices, National Currency)            MMK 721,384.39 .       MMK 797,836.85 .       MMK 882,454.45 .     MMK 976,115.75 .          MMK 1,079,794.52 .
   7   GDP Per Capita (Current Prices, US Dollars)                   US$ 839.475            US$ 859.7                 US$ 880.472       US$ 901.81                US$ 923.723
   8   GDP (PPP), US Dollars                                         US$ 87.221 Billion     US$ 93.348 Billion    US$ 100.102 Billion US$ 107.579 Billion         US$ 115.748 Billion
   9   GDP Per Capita (PPP), US Dollars                              US$ 1,369.85           US$ 1,437.19             US$ 1,510.80       US$ 1,591.66              US$ 1,678.79
  10   GDP Share of World Total (PPP)                                0.10%                  0.11%                        0.00105        0.00106                   0.11%
  11   Implied PPP Conversion Rate                                   526.615                555.138                      584.096        613.27                    643.2
  12   Investment (% of GDP)                                         13.51%                 12.93%                       0.12688        0.12618                   12.59%
  13   Gross National Savings (% of GDP)                             16.26%                 15.83%                       0.17977        0.17967                   14.15%
  14   Inflation, Average Consumer Prices (Indexed to Year 2000)     2,223.42 (Index, Base 2,401.31 (Index,      2,593.44 (Index, Base 2,800.93 (Index, Base      3,025.03 (Index, Base Year
                                                                     Year 2000 = 100)      Base Year 2000 =        Year 2000 = 100) Year 2000 = 100)              2000 = 100)
                                                                                           100)
  15 Inflation (Average Consumer Price Change %)                     8.25%                 8.00%                 8.00%                  8.00%                     8.00%
  16 Inflation, End of Year (Indexed to Year 2000)                   2,184.02 (Index, Base 2,358.75 (Index,      2,547.47 (Index, Base 2,751.29 (Index, Base      2,971.41 (Index, Base Year
                                                                     Year 2000 = 100)      Base Year 2000 =        Year 2000 = 100) Year 2000 = 100)              2000 = 100)
                                                                                           100)
  17 Inflation (End of Year Change %)                                8.00%                 8.00%                         0.08001        0.08001                   8.00%
  18 Import Volume of All Items Including Goods and Services (Percent 4.73%                 4.77%                        -0.00767       -0.00798                  -0.69%
       Change)
  19   Import Volumes of Goods Only (Percent Change)                  8.66%                 6.22%                            0          0                         0%
  20 Export Volume of All Items Including Goods and Services (Percent 14.77%                48.71%                       0.00271        0.00711                   0.64%
       Change)
Year 2012             Year 2013           Year 2014              Year 2015                Year 2016
21   Export Volumes of Goods Only (Percent Change)               14.42%                49.97%                          0          0                        0%
22   Value of Oil Imports                                        US$ 1.431 Billions    US$ 1.56 Billions     US$ 1.664 Billions US$ 1.77 Billions          US$ 1.884 Billions
23   Value of Oil Exports                                        US$ -- Billions       US$ -- Billions         US$ -- Billions    US$ -- Billions          US$ -- Billions
24   Unemployment Rate (% of Labour Force)                       4.02%                 4.02%                       0.0402         0.0402                   4.02%
25   Population                                                  63.672 Million        64.952 Million          66.257 Million     67.589 Million           68.948 Million
26   General government revenue (National Currency)              MMK 3,060.03 Billions. MMK 3,452.72       MMK 3,936.99 Billions. MMK 4,499.01 Billions.   MMK 5,127.83 Billions.
                                                                                        Billions.
27 General government revenue (% of GDP)                         6.66%                  6.66%                     0.06733         0.06819                  6.89%
28 General government total expenditure (National Currency)      MMK 4,582.86 Billions. MMK 4,987.38       MMK 5,590.00 Billions. MMK 6,334.78 Billions.   MMK 7,233.47 Billions.
                                                                                        Billions.
29 General government total expenditure (% of GDP)               9.98%                  9.62%                     0.09561         0.09602                  9.72%
30 Total Government Net Lending/ Borrowing (National Currency) MMK -1,522.83 Billions. MMK -1,534.66       MMK -1,653.01 Billions. MMK -1,835.77 Billions. MMK -2,105.65 Billions.
                                                                                       Billions.
31 Total Government Net Lending/ Borrowing (% of GDP)            -3.32%                -2.96%                    -0.02827         -0.02783                 -2.83%
32 Total Government Gross Debt (National Currency)               MMK 21,978.24 Billion. MMK 25,264.67      MMK 28,776.90 Billion. MMK 29,478.91 Billion.   MMK 32,897.38 Billion.
                                                                                        Billion.
33 Total Government Gross Debt (% of GDP)                        47.85%                 48.75%                    0.49217         0.44682                  44.19%
34 Fiscal Year Gross Domestic Product, Current Prices            MMK 45,931.80         MMK 51,820.81          MMK 58,469.01 MMK 65,974.81 Billions. MMK 74,449.42 Billions.
                                                                 Billions.             Billions.                 Billions.
35 Current Account Balance (US Dollars)                          US$ -2.425 Billion    US$ 0.646 Billion     US$ 1.893 Billion US$ 2.266 Billion    US$ 3.232 Billion
36 Current Account Balance (% GDP)                               -4.54%                1.16%                      0.03244         0.03717                  5.08%
Sales Projections for Myanmar
     Pharmaceutical Markets for 2013-14
                                   Sales Projection

         Others


           CNS


    Respiratory


  Endocardinal


Gastrointestinal
                                                                        Sales Projection

 Cardiovascular


     Analgesics


      Vitamins


  Anti Infective

                   0%   5%   10%   15%      20%       25%   30%   35%
Expenses for Registration of Pharmaceutical Company
                       or Drug Product

•    Expense Head :
•    Registration of Pharmaceutical Company:
•    10- 15 Lacs
•    Registration of Pharmaceutical product:
•    30-45 Lacs
•    Agents basis : 40-45 Lacs depending upon the
     type of the Product to be registered
References
• Financial Express Dhaka :
• Economic Times
• Union of Myanmar, Minisitry of Health, Department of Health, Food And
  Drug Administration Medipower Myanmar, Burma
• Thank You

More Related Content

What's hot

Pharmaceutical marketing course
Pharmaceutical marketing coursePharmaceutical marketing course
Pharmaceutical marketing courseMadhukar Tanna
 
South East Asia Pharmaceutical Markets Jamie Davies October 2014
South East Asia Pharmaceutical Markets Jamie Davies October 2014South East Asia Pharmaceutical Markets Jamie Davies October 2014
South East Asia Pharmaceutical Markets Jamie Davies October 2014jamiedavies12345
 
Pharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & IndianPharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & Indianprateek_floyd
 
Digital Pharma: Evolution and Revolution in Marketing & Sales
Digital Pharma: Evolution and Revolution in Marketing & SalesDigital Pharma: Evolution and Revolution in Marketing & Sales
Digital Pharma: Evolution and Revolution in Marketing & SalesLen Starnes
 
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Brand plan for 2010   glycomet (us vitamin) - mitesh shahBrand plan for 2010   glycomet (us vitamin) - mitesh shah
Brand plan for 2010 glycomet (us vitamin) - mitesh shahMitesh Shah
 
Ensuring Profitable ROI in Pharma Marketing (mini)
Ensuring Profitable ROI in Pharma Marketing (mini)Ensuring Profitable ROI in Pharma Marketing (mini)
Ensuring Profitable ROI in Pharma Marketing (mini)Eularis
 
South East Asia’s Pharmerging Landscape presentation given at the SEA Pharmac...
South East Asia’s Pharmerging Landscape presentation given at the SEA Pharmac...South East Asia’s Pharmerging Landscape presentation given at the SEA Pharmac...
South East Asia’s Pharmerging Landscape presentation given at the SEA Pharmac...QuintilesIMS Asia Pacific
 
The philippines market research presentation
The philippines market research presentationThe philippines market research presentation
The philippines market research presentationNadia Dias
 
marketing & sales roles for the pharma industries
marketing & sales roles for the pharma industriesmarketing & sales roles for the pharma industries
marketing & sales roles for the pharma industriesAbhilash Vangari
 
Pharma marketing
Pharma marketingPharma marketing
Pharma marketingUzair Ahmed
 
Pharmaceutical Marketing in the New Age
Pharmaceutical Marketing in the New AgePharmaceutical Marketing in the New Age
Pharmaceutical Marketing in the New AgeAnup Soans
 
Pharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyPharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyAwais e Siraj
 
10 ten best, average and worst Points of Pharmaceutical marketing
10 ten best, average and worst Points of Pharmaceutical marketing10 ten best, average and worst Points of Pharmaceutical marketing
10 ten best, average and worst Points of Pharmaceutical marketingAnjum Iqbal
 
Pharmaceutical Regulations in GCC countries
Pharmaceutical Regulations in GCC countriesPharmaceutical Regulations in GCC countries
Pharmaceutical Regulations in GCC countriesIman Ajami
 

What's hot (20)

Pharmaceutical marketing course
Pharmaceutical marketing coursePharmaceutical marketing course
Pharmaceutical marketing course
 
case study-pharma
case study-pharmacase study-pharma
case study-pharma
 
South East Asia Pharmaceutical Markets Jamie Davies October 2014
South East Asia Pharmaceutical Markets Jamie Davies October 2014South East Asia Pharmaceutical Markets Jamie Davies October 2014
South East Asia Pharmaceutical Markets Jamie Davies October 2014
 
Pharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & IndianPharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & Indian
 
Digital Pharma: Evolution and Revolution in Marketing & Sales
Digital Pharma: Evolution and Revolution in Marketing & SalesDigital Pharma: Evolution and Revolution in Marketing & Sales
Digital Pharma: Evolution and Revolution in Marketing & Sales
 
Medical Affairs Excellence Services Summary
Medical Affairs Excellence Services SummaryMedical Affairs Excellence Services Summary
Medical Affairs Excellence Services Summary
 
Pharmaceutical Marketing Strategies
Pharmaceutical Marketing StrategiesPharmaceutical Marketing Strategies
Pharmaceutical Marketing Strategies
 
Esomeprazole plan
Esomeprazole planEsomeprazole plan
Esomeprazole plan
 
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Brand plan for 2010   glycomet (us vitamin) - mitesh shahBrand plan for 2010   glycomet (us vitamin) - mitesh shah
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
 
Marketing Plan
Marketing PlanMarketing Plan
Marketing Plan
 
Ensuring Profitable ROI in Pharma Marketing (mini)
Ensuring Profitable ROI in Pharma Marketing (mini)Ensuring Profitable ROI in Pharma Marketing (mini)
Ensuring Profitable ROI in Pharma Marketing (mini)
 
South East Asia’s Pharmerging Landscape presentation given at the SEA Pharmac...
South East Asia’s Pharmerging Landscape presentation given at the SEA Pharmac...South East Asia’s Pharmerging Landscape presentation given at the SEA Pharmac...
South East Asia’s Pharmerging Landscape presentation given at the SEA Pharmac...
 
The philippines market research presentation
The philippines market research presentationThe philippines market research presentation
The philippines market research presentation
 
marketing & sales roles for the pharma industries
marketing & sales roles for the pharma industriesmarketing & sales roles for the pharma industries
marketing & sales roles for the pharma industries
 
Pharma marketing
Pharma marketingPharma marketing
Pharma marketing
 
Pharmaceutical Marketing in the New Age
Pharmaceutical Marketing in the New AgePharmaceutical Marketing in the New Age
Pharmaceutical Marketing in the New Age
 
Pharmaceutical Sales in Pakistan
Pharmaceutical Sales in PakistanPharmaceutical Sales in Pakistan
Pharmaceutical Sales in Pakistan
 
Pharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyPharmaceutical Marketing Strategy
Pharmaceutical Marketing Strategy
 
10 ten best, average and worst Points of Pharmaceutical marketing
10 ten best, average and worst Points of Pharmaceutical marketing10 ten best, average and worst Points of Pharmaceutical marketing
10 ten best, average and worst Points of Pharmaceutical marketing
 
Pharmaceutical Regulations in GCC countries
Pharmaceutical Regulations in GCC countriesPharmaceutical Regulations in GCC countries
Pharmaceutical Regulations in GCC countries
 

Similar to Myanmar Pharmaceutical Market Overview

Why did d-penicillamine disappear from the market?
Why did d-penicillamine disappear from the market?Why did d-penicillamine disappear from the market?
Why did d-penicillamine disappear from the market?Sanjeev Kumar
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdfASSAM DOWN TOWN UNIVERSITY
 
Detection,Reporting and Management of Adverse Drug Reactions Pharmacy College...
Detection,Reporting and Management of Adverse Drug Reactions Pharmacy College...Detection,Reporting and Management of Adverse Drug Reactions Pharmacy College...
Detection,Reporting and Management of Adverse Drug Reactions Pharmacy College...prabhakar patil
 
Understanding Political and Economic aspect of modern medicine and the use of...
Understanding Political and Economic aspect of modern medicine and the use of...Understanding Political and Economic aspect of modern medicine and the use of...
Understanding Political and Economic aspect of modern medicine and the use of...Naveen Bhartiya
 
Oncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End UserOncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End UserPharmacy @ Institut Kanser Negara
 
Bodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdscoBodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdscochiranjibi68
 
Drug Bulletin Of Nepal
Drug Bulletin Of Nepal Drug Bulletin Of Nepal
Drug Bulletin Of Nepal Niraj Bartaula
 
A Report on Department of Drug Administration and National Medicine Laborator...
A Report on Department of Drug Administration and National Medicine Laborator...A Report on Department of Drug Administration and National Medicine Laborator...
A Report on Department of Drug Administration and National Medicine Laborator...Nabin Bist
 
The Indian in vitro diagnostic market - an overview
The Indian in vitro diagnostic market - an overviewThe Indian in vitro diagnostic market - an overview
The Indian in vitro diagnostic market - an overviewSchenella Menda
 
REGULATORY REQUIREMENTS FOR MHRA detail .pptx
REGULATORY REQUIREMENTS FOR MHRA detail .pptxREGULATORY REQUIREMENTS FOR MHRA detail .pptx
REGULATORY REQUIREMENTS FOR MHRA detail .pptxnivedithag131
 
Japan drug and cosmetics regulation.pdf
 Japan drug and cosmetics  regulation.pdf Japan drug and cosmetics  regulation.pdf
Japan drug and cosmetics regulation.pdfBhavikaAPatel
 
Regulatory Affairs by Chandra Mohan
Regulatory Affairs by Chandra MohanRegulatory Affairs by Chandra Mohan
Regulatory Affairs by Chandra MohanChandra Mohan
 
Activity ppt (group 89 96) A macro view on INDIA'S PHARMACEUTICAL INDUSTRY & ...
Activity ppt (group 89 96) A macro view on INDIA'S PHARMACEUTICAL INDUSTRY & ...Activity ppt (group 89 96) A macro view on INDIA'S PHARMACEUTICAL INDUSTRY & ...
Activity ppt (group 89 96) A macro view on INDIA'S PHARMACEUTICAL INDUSTRY & ...SOURAV MADHAV SURYAWANSHI
 
Pdmp 2 small kim_lev_zarate
Pdmp 2 small kim_lev_zaratePdmp 2 small kim_lev_zarate
Pdmp 2 small kim_lev_zarateOPUNITE
 
Mining of DPCO 2013
Mining of DPCO 2013Mining of DPCO 2013
Mining of DPCO 2013Dhwni Sheth
 
Thailand situational assessment2015
Thailand situational assessment2015Thailand situational assessment2015
Thailand situational assessment2015Chuchai Sornchumni
 

Similar to Myanmar Pharmaceutical Market Overview (20)

Why did d-penicillamine disappear from the market?
Why did d-penicillamine disappear from the market?Why did d-penicillamine disappear from the market?
Why did d-penicillamine disappear from the market?
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf
 
Detection,Reporting and Management of Adverse Drug Reactions Pharmacy College...
Detection,Reporting and Management of Adverse Drug Reactions Pharmacy College...Detection,Reporting and Management of Adverse Drug Reactions Pharmacy College...
Detection,Reporting and Management of Adverse Drug Reactions Pharmacy College...
 
Understanding Political and Economic aspect of modern medicine and the use of...
Understanding Political and Economic aspect of modern medicine and the use of...Understanding Political and Economic aspect of modern medicine and the use of...
Understanding Political and Economic aspect of modern medicine and the use of...
 
Oncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End UserOncology Drugs: The journey From Manufacturer To The End User
Oncology Drugs: The journey From Manufacturer To The End User
 
Bodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdscoBodies regulating indian pharmaceutical sector, cdsco
Bodies regulating indian pharmaceutical sector, cdsco
 
Drug Bulletin Of Nepal
Drug Bulletin Of Nepal Drug Bulletin Of Nepal
Drug Bulletin Of Nepal
 
A Report on Department of Drug Administration and National Medicine Laborator...
A Report on Department of Drug Administration and National Medicine Laborator...A Report on Department of Drug Administration and National Medicine Laborator...
A Report on Department of Drug Administration and National Medicine Laborator...
 
Pharmaceutical Marketing
Pharmaceutical MarketingPharmaceutical Marketing
Pharmaceutical Marketing
 
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
Session 3: Salmah Bahri - Ministry of Health, Malaysia / Monitoring of Counte...
 
The Indian in vitro diagnostic market - an overview
The Indian in vitro diagnostic market - an overviewThe Indian in vitro diagnostic market - an overview
The Indian in vitro diagnostic market - an overview
 
REGULATORY REQUIREMENTS FOR MHRA detail .pptx
REGULATORY REQUIREMENTS FOR MHRA detail .pptxREGULATORY REQUIREMENTS FOR MHRA detail .pptx
REGULATORY REQUIREMENTS FOR MHRA detail .pptx
 
Japan drug and cosmetics regulation.pdf
 Japan drug and cosmetics  regulation.pdf Japan drug and cosmetics  regulation.pdf
Japan drug and cosmetics regulation.pdf
 
Regulatory Affairs by Chandra Mohan
Regulatory Affairs by Chandra MohanRegulatory Affairs by Chandra Mohan
Regulatory Affairs by Chandra Mohan
 
Introduction to post marketing drug safety surveillance fda 2-11-14
Introduction to post marketing drug safety surveillance fda 2-11-14Introduction to post marketing drug safety surveillance fda 2-11-14
Introduction to post marketing drug safety surveillance fda 2-11-14
 
Activity ppt (group 89 96) A macro view on INDIA'S PHARMACEUTICAL INDUSTRY & ...
Activity ppt (group 89 96) A macro view on INDIA'S PHARMACEUTICAL INDUSTRY & ...Activity ppt (group 89 96) A macro view on INDIA'S PHARMACEUTICAL INDUSTRY & ...
Activity ppt (group 89 96) A macro view on INDIA'S PHARMACEUTICAL INDUSTRY & ...
 
Pdmp 2 small kim_lev_zarate
Pdmp 2 small kim_lev_zaratePdmp 2 small kim_lev_zarate
Pdmp 2 small kim_lev_zarate
 
Mining of DPCO 2013
Mining of DPCO 2013Mining of DPCO 2013
Mining of DPCO 2013
 
Competing with Generics | Life Sciences Practice | UC STRATEGY
Competing with Generics | Life Sciences Practice | UC STRATEGYCompeting with Generics | Life Sciences Practice | UC STRATEGY
Competing with Generics | Life Sciences Practice | UC STRATEGY
 
Thailand situational assessment2015
Thailand situational assessment2015Thailand situational assessment2015
Thailand situational assessment2015
 

More from Ishan Shukla

Regulatory Perspective for entering Global Pharma Markets Ishan Shukla
Regulatory Perspective for entering Global Pharma Markets Ishan ShuklaRegulatory Perspective for entering Global Pharma Markets Ishan Shukla
Regulatory Perspective for entering Global Pharma Markets Ishan ShuklaIshan Shukla
 
505 b 2 strategy and Rx to otc switch market overview = ishan shukla
505 b 2 strategy and Rx to otc switch market overview = ishan shukla505 b 2 strategy and Rx to otc switch market overview = ishan shukla
505 b 2 strategy and Rx to otc switch market overview = ishan shuklaIshan Shukla
 
Road to commercial success –the target product profile basics part 1 ishan sh...
Road to commercial success –the target product profile basics part 1 ishan sh...Road to commercial success –the target product profile basics part 1 ishan sh...
Road to commercial success –the target product profile basics part 1 ishan sh...Ishan Shukla
 
Opthalmology market an oppertunity and overview 1
Opthalmology market   an oppertunity and overview 1Opthalmology market   an oppertunity and overview 1
Opthalmology market an oppertunity and overview 1Ishan Shukla
 
Nasal drug delivery sytem 1
Nasal drug delivery sytem 1Nasal drug delivery sytem 1
Nasal drug delivery sytem 1Ishan Shukla
 
Ivf market trends and an overview
Ivf   market trends and an overviewIvf   market trends and an overview
Ivf market trends and an overviewIshan Shukla
 

More from Ishan Shukla (6)

Regulatory Perspective for entering Global Pharma Markets Ishan Shukla
Regulatory Perspective for entering Global Pharma Markets Ishan ShuklaRegulatory Perspective for entering Global Pharma Markets Ishan Shukla
Regulatory Perspective for entering Global Pharma Markets Ishan Shukla
 
505 b 2 strategy and Rx to otc switch market overview = ishan shukla
505 b 2 strategy and Rx to otc switch market overview = ishan shukla505 b 2 strategy and Rx to otc switch market overview = ishan shukla
505 b 2 strategy and Rx to otc switch market overview = ishan shukla
 
Road to commercial success –the target product profile basics part 1 ishan sh...
Road to commercial success –the target product profile basics part 1 ishan sh...Road to commercial success –the target product profile basics part 1 ishan sh...
Road to commercial success –the target product profile basics part 1 ishan sh...
 
Opthalmology market an oppertunity and overview 1
Opthalmology market   an oppertunity and overview 1Opthalmology market   an oppertunity and overview 1
Opthalmology market an oppertunity and overview 1
 
Nasal drug delivery sytem 1
Nasal drug delivery sytem 1Nasal drug delivery sytem 1
Nasal drug delivery sytem 1
 
Ivf market trends and an overview
Ivf   market trends and an overviewIvf   market trends and an overview
Ivf market trends and an overview
 

Recently uploaded

call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 

Recently uploaded (20)

call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 

Myanmar Pharmaceutical Market Overview

  • 1. Myanmar Pharmaceutical Market An over View
  • 2. Myanmar Health Care Information Myanmar Overview • Mandalay • Meikhtila • Pakokku • Monywa • Yangon • Moegok • Mawlamyine • Myitkyinar • Bago • Taunggyi • Pyay • Lashio • Pathein • Myeik • Sittway • Taungu
  • 3. Myanmar Pharmaceutical Market Overview • Estimated pharmaceutical market size is about US$ 100-120 millions CIF value. • Indian Pharma Companies are about 35 % of the total market. • Leading Indian players are Ranbaxy, Cipla, Dr.Reddy’s…..etc. • Multi National Companies are less active directly. • Two major cities (Ygn & Mdy) contribute 60 % of total sales of Pharma Market. • District areas contribute remaining 40% • Growing awareness of Health care & modern life style in Major cities are increasing. • Number of Private Hospitals & pharmacies are increasing as well. • Some international hospitals like Bumrungrad Hospital, Bangkok Hospital are coming up. • Prescription drugs can be sold in open market.
  • 4. Myanmar Pharmaceutical Market YANGON, Mar 30 (Xinhua): Pharmaceutical products from Asian countries are dominating Myanmar's consumers market with India standing as the country's largest pharmaceutical products importing country, the local weekly Flower News reported today. Accounting for 40 per cent of Myanmar's pharmaceuticals import, India is followed by Bangladesh, China, Thailand, Indonesia, Pakistan and Vietnam. According to the statistics of the Ministry of Commerce, Myanmar imported over 5,000 categories of pharmaceutical products annually. In the fiscal year 2007-08, Myanmar imported pharmaceutical products worth of 115.56 million U.S. dollars, an increase of 15.5 per cent from 2006-07, earlier statistics shows. Meanwhile, Myanmar's largest and most modern pharmaceutical factory in the northern city of Pyin Oo Lwin was established in December 2007 producing 162 kinds of medicines.
  • 5. With the aim of reducing import-substitute medicines, the Pyin Oo Lwin Pharmaceutical Factory under the Ministry of Industry-1, produce high-quality modern medicines such as tablet, capsule, intramuscular, intravenous, lotion and powder. There has been some five other pharmaceutical factories in Myanmar, including two special ones, respectively located in Yangon, Sagaing and Inyaung. These factories are producing medicines that supply 40 per cent of the domestic market. Moreover, a famous Myanmar private pharmaceutical company, FAME, will produce seasonal medicines for Japan and South Korea as proposed by the two countries. FAME is known as the first private pharmaceutical factory in Myanmar whose products meet the stringent Good Manufacturing Practices (GMP) standards set by the World Health Organisation ( WHO). The company produces 45 different kinds of Myanmar traditional herbal medicines and its products were exported to countries or regions such as Malaysia, Singapore, Thailand, Taiwan, South Korea , Germany and Japan
  • 6. Myanmar Pharmaceutical Market 2011-12 Market Share Therapeutical Segment wise Sr.No Therapeutical Segement Market share 1 Anti Infective 35% 2 Vitamins 30% Anti Infective 2% 3 Analgesics 11% 2% 3% 3%4% Vitamins Analgesics 35% 4 Cardiovascular 10% 10% Cardiovascular Gastrointestinal 5 Gastrointestinal 3% 11% Endocardinal Respiratory 6 Endocardinal 2% 30% CNS Others 7 Respiratory 3% 8 CNS 4% 9 Others 2%
  • 7. Share of Export Countries in Myanmar Pharmaceutical Market 2011-12 Share of Countries Sr.No Countries Share 1 India 33% Others 2 Thailand 15% France 3 Phillipines 6% USA 4 UK 5% China 5 Indonesia 4% Korea Myanmar 6 Myanmar 4% Share Indonesia 7 Korea 4% UK 8 China 4% Phillipines 9 USA 3% Thailand 10 France 3% India 11 Others 18% 0% 10% 20% 30% 40%
  • 8. Hospital Data • Medical & Health Facilities & Personnel • Doctors in Myanmar 1 No of Drs in State service 6331 1 Approximate Specialist Hospital 35 2 No of Drs in Private practice 11145 2 Hospital with specialist service 29 Total 17476 3 Hospital above 25 bedded 302 Total 366
  • 9. UNION OF MYANMAR Ministry of Health Department of Health Food and Drug Administration Office No(47),Nay Pyi Taw, Myanmar Registration Procedure • Toapply name registration for assessment fees ( It will take 10 days or 14 days ) • After getting assessment fees documents from FDA, to remit assessment fees on Monday and Wednesday only at FDA. - Monday ( variation fees, assessment fees, registration fees ) - Wednesday ( assessment fees, registration fees ) • After remitting the assessment fees, to apply FDA permit ( It will take 10 days ) • After getting FDA permit, to apply FOC Trade permit at Airport Trade Office. ( It will take 2-3 days only ) - Need to apply Trade permit if the weight of samples is too much. (or) if the products too much for samples dispatching. • After getting FDA permit and Trade permit, to inform to dispatch the samples and to submit at FDA. • After submitting the samples, to submit the dossiers.
  • 10. • - For dossier submission, - Need to take number upto 9:30 am on Tuesday for renwal and on Thursday for new product. - Firstly FDA accept the dossiers without checking details and unlimited dossier qty. - Up to 3 pm only. ( renewal on Tuesday/new on Thursday ) - Then, after two weeks, FDA issue the preview for the complete dossier, and return back the incomplete dossier to whom concern. Time is from 3 pm to 4:30 pm. • Next, two weeks, can pay lab test fees. • After paid lab test fees, our product is under registration process and have to follow up and have to wait for approval. • After getting approval, to pay registration fees. • After two months, we will get DRC. - After getting DRC, to apply attachment for DIAC. ( It will take 3 weeks. )
  • 11. Import Procedure for Medicines in Myanmar • STEP I • Application of import price confirmation at MPMEEA ( Myanmar Pharmaceutical & Medical Equipment Entrepreneurs' Association ) • Documents required: • Data format form issued by MPMEEA for application • Usage of Medicine • Respective Original Drug Registration Certificate ( DRC ) issued by Myanmar Food and Drug Board of Authority • Original Drug Importation Approval Certificate ( DIAC ) issued by Myanmar Food and Drug Board of Authority of import applied company • Membership Certificate of MPMEEA • Database CD contained all import data of respective item ( soft & hard copies ) • Process running time at MPMEEA: Two days if all documents are correct • STEP II • Date entry process at import section ( Yangon ) under Ministry of Commerce • Documents required: • Import application document • Self commitment for import price confirmation • Usage of Medicine • Proforma Invoice • Sale Contract • Import price confirmation endorsed by MPMEEA • Market price record for respective medicine • Process running time at import section ( Yangon ) : Two days if all documents are correct.
  • 12. STEP - III • Bank Credit inspection and online data entry at import section ( Yangon ) under Ministry of Commerce • Documents required for Bank credit inspection : • Application letter • Original bank credit slip and two copies • Bank original passport and one copy • Process running time for bank credit inspection: One day if all documents are correct. • Documents required for online data entry: • Copy of proforma invoice • Copy of Sale Contract • Copy of Certificate of Exporter/Importer Registration issued by Directorate of Trade, Ministry of Commerce • Usage of medicine • Company distribution price for respective medicine • Bank credit slip • Self commitment for import price confirmation • Custom H S Code for Section One ( Medicine ) • Process running time for online data entry: One day if all documents are correct.
  • 13. STEP IV • Final import application at import section under Ministry of Commerce in Naypyitaw ( capital of Union of Myanmar ) • Documents required: • Import application with company letter head • Online data entry record ( Original ) • Proforma invoice • Sale Contract • Bank credit slip • Usage of medicine • Company distribution price for respective medicine • BOD list of import company • Import price confirmation endorsed by MPMEEA • Copy of Certificate of Exporter/Importer Registration issued by Directorate of Trade, Ministry of Commerce • Respective Drug Registration Certificate ( DRC ) issued by Myanmar Food and Drug Board of Authority • Drug Importation Approval Certificate ( DIAC ) issued by Myanmar Food and Drug Board of Authority of import applied company • Data Format Chart of Export Income • Process running time: Two weeks if all documents are correct.
  • 14. STEP V • L/C opening procedure at Myanma Foreign Trade Bank, Yangon ( MFTB ) or Myanma Investment and Commercial Bank, Yangon ( MICB ) • Documents required: Original import licence issued by Ministry of Commerce • L/C data entry form issued by banks • copy of Proforma invoice • Cheque ( 2 sets ) • Bank passport ( 2 copies ) • Import license original and one copy • Two copies of Proforma Invoice • Process running time: Three days if all documents are correct.
  • 15. Economical Indicators of Myanmar Market Myanmar Population Growth Rate, Birth Rate, Death Rate, Net Migration Rate Myanmar Age Structure, Median Age, Gender and Urbanization Myanmar Life Expectancy Rate, Infant Mortality Rate and Total Fertility Rate Myanmar HIV, AIDS and Other Major Infectious Disease Rates Myanmar Industries and Industrial Growth Production Rate
  • 16. Economical Indicators of Myanmar • Myanmar Population Growth Rate, Birth Rate, Death Rate, Net Migration Rate : • Population growth rate: 1.084% • Birth rate: 19.31 births/1,000 population • Death rate: 8.16 deaths/1,000 population • Net migration rate: -0.31 migrant(s)/1,000 population • Myanmar Age Structure, Median Age, Gender and Urbanization : • Age structure: 0-14 years: 27.5% (male 7,560,859/female 7,278,652) • 5-64 years: 67.5% (male 18,099,707/female 18,342,696) • 65 years and over: 5% (male 1,184,291/female 1,533,599) • Median Age: total: 26.9 years male: 26.3 years female: 27.5 years • Sex ratio: at birth: 1.06 male(s)/female under 15 years: 1.04 male(s)/female • 15-64 years: 0.99 male(s)/female 65 years and over: 0.77 male(s)/female • total population: 0.99 male(s)/female
  • 17. Economical Indicators of Myanmar • Myanmar Life Expectancy Rate, Infant Mortality Rate and Total Fertility Rate : • Life expectancy at birth: total population: 64.88 years male: 62.57 years female: 67.33 years • Infant mortality rate: total: 49.23 deaths/1,000 live births male: 56.16 deaths/1,000 live births female: 41.88 deaths/1,000 live births • Total fertility rate: 2.26 children born/woman • Myanmar HIV, AIDS and Other Major Infectious Disease Rates : • HIV/AIDS - adult prevalence rate: 0.6% • HIV/AIDS - people living with HIV/AIDS: 240,000 • HIV/AIDS - deaths: 18,000 • Major infectious diseases: degree of risk: • very high food or waterborne diseases: • bacterial and protozoal diarrhea, hepatitis A, and typhoid fever vectorborne diseases: • dengue fever and malaria water contact disease: leptospirosis animal contact disease: rabies note: highly pathogenic H5N1 avian influenza has been identified in this country; • it poses a negligible risk with extremely rare cases possible among US citizens who have close contact with birds
  • 18. Economical Indicators of Myanmar • Myanmar Industries and Industrial Growth Production Rate : • Industries: agricultural processing; wood and wood products; • copper, tin, tungsten, iron; cement, construction materials; • pharmaceuticals; fertilizer; oil and natural gas; garments, • jade and gems • Industrial production growth rate: 4.3%
  • 19. Economical Indicator Forecast up to 2016 for Myanmar Markets
  • 20. Year 2012 Year 2013 Year 2014 Year 2015 Year 2016 Sr. No. Economic Indicator Listing for Myanmar Indicator Value Indicator Value Indicator Value Indicator Value Indicator Value 1 GDP Growth (Constant Prices, National Currency) 5.50% 5.67% 5.68% 5.68% 5.69% 2 GDP (Current Prices, National Currency) MMK 45,931.80 Billion. MMK 51,820.81 MMK 58,469.01 Billion. MMK 65,974.81 Billion. MMK 74,449.42 Billion. Billion. 3 GDP (Current Prices, US Dollars) US$ 53.451 Billion US$ 55.839 Billion US$ 58.338 Billion US$ 60.953 Billion US$ 63.689 Billion 4 GDP Deflator 608 (Index, Base Year 649.159 (Index, Base 693.104 (Index, Base 740.023 (Index, Base Year 790.119 (Index, Base Year as per country's Year as per country's Year as per country's as per country's accounts as per country's accounts = accounts = 100) accounts = 100) accounts = 100) = 100) 100) 5 GDP Per Capita (Constant Prices, National Currency) MMK 118,648.72 . MMK 122,903.20 . MMK 127,319.28 . MMK 131,903.40 . MMK 136,662.25 . 6 GDP Per Capita (Current Prices, National Currency) MMK 721,384.39 . MMK 797,836.85 . MMK 882,454.45 . MMK 976,115.75 . MMK 1,079,794.52 . 7 GDP Per Capita (Current Prices, US Dollars) US$ 839.475 US$ 859.7 US$ 880.472 US$ 901.81 US$ 923.723 8 GDP (PPP), US Dollars US$ 87.221 Billion US$ 93.348 Billion US$ 100.102 Billion US$ 107.579 Billion US$ 115.748 Billion 9 GDP Per Capita (PPP), US Dollars US$ 1,369.85 US$ 1,437.19 US$ 1,510.80 US$ 1,591.66 US$ 1,678.79 10 GDP Share of World Total (PPP) 0.10% 0.11% 0.00105 0.00106 0.11% 11 Implied PPP Conversion Rate 526.615 555.138 584.096 613.27 643.2 12 Investment (% of GDP) 13.51% 12.93% 0.12688 0.12618 12.59% 13 Gross National Savings (% of GDP) 16.26% 15.83% 0.17977 0.17967 14.15% 14 Inflation, Average Consumer Prices (Indexed to Year 2000) 2,223.42 (Index, Base 2,401.31 (Index, 2,593.44 (Index, Base 2,800.93 (Index, Base 3,025.03 (Index, Base Year Year 2000 = 100) Base Year 2000 = Year 2000 = 100) Year 2000 = 100) 2000 = 100) 100) 15 Inflation (Average Consumer Price Change %) 8.25% 8.00% 8.00% 8.00% 8.00% 16 Inflation, End of Year (Indexed to Year 2000) 2,184.02 (Index, Base 2,358.75 (Index, 2,547.47 (Index, Base 2,751.29 (Index, Base 2,971.41 (Index, Base Year Year 2000 = 100) Base Year 2000 = Year 2000 = 100) Year 2000 = 100) 2000 = 100) 100) 17 Inflation (End of Year Change %) 8.00% 8.00% 0.08001 0.08001 8.00% 18 Import Volume of All Items Including Goods and Services (Percent 4.73% 4.77% -0.00767 -0.00798 -0.69% Change) 19 Import Volumes of Goods Only (Percent Change) 8.66% 6.22% 0 0 0% 20 Export Volume of All Items Including Goods and Services (Percent 14.77% 48.71% 0.00271 0.00711 0.64% Change)
  • 21. Year 2012 Year 2013 Year 2014 Year 2015 Year 2016 21 Export Volumes of Goods Only (Percent Change) 14.42% 49.97% 0 0 0% 22 Value of Oil Imports US$ 1.431 Billions US$ 1.56 Billions US$ 1.664 Billions US$ 1.77 Billions US$ 1.884 Billions 23 Value of Oil Exports US$ -- Billions US$ -- Billions US$ -- Billions US$ -- Billions US$ -- Billions 24 Unemployment Rate (% of Labour Force) 4.02% 4.02% 0.0402 0.0402 4.02% 25 Population 63.672 Million 64.952 Million 66.257 Million 67.589 Million 68.948 Million 26 General government revenue (National Currency) MMK 3,060.03 Billions. MMK 3,452.72 MMK 3,936.99 Billions. MMK 4,499.01 Billions. MMK 5,127.83 Billions. Billions. 27 General government revenue (% of GDP) 6.66% 6.66% 0.06733 0.06819 6.89% 28 General government total expenditure (National Currency) MMK 4,582.86 Billions. MMK 4,987.38 MMK 5,590.00 Billions. MMK 6,334.78 Billions. MMK 7,233.47 Billions. Billions. 29 General government total expenditure (% of GDP) 9.98% 9.62% 0.09561 0.09602 9.72% 30 Total Government Net Lending/ Borrowing (National Currency) MMK -1,522.83 Billions. MMK -1,534.66 MMK -1,653.01 Billions. MMK -1,835.77 Billions. MMK -2,105.65 Billions. Billions. 31 Total Government Net Lending/ Borrowing (% of GDP) -3.32% -2.96% -0.02827 -0.02783 -2.83% 32 Total Government Gross Debt (National Currency) MMK 21,978.24 Billion. MMK 25,264.67 MMK 28,776.90 Billion. MMK 29,478.91 Billion. MMK 32,897.38 Billion. Billion. 33 Total Government Gross Debt (% of GDP) 47.85% 48.75% 0.49217 0.44682 44.19% 34 Fiscal Year Gross Domestic Product, Current Prices MMK 45,931.80 MMK 51,820.81 MMK 58,469.01 MMK 65,974.81 Billions. MMK 74,449.42 Billions. Billions. Billions. Billions. 35 Current Account Balance (US Dollars) US$ -2.425 Billion US$ 0.646 Billion US$ 1.893 Billion US$ 2.266 Billion US$ 3.232 Billion 36 Current Account Balance (% GDP) -4.54% 1.16% 0.03244 0.03717 5.08%
  • 22. Sales Projections for Myanmar Pharmaceutical Markets for 2013-14 Sales Projection Others CNS Respiratory Endocardinal Gastrointestinal Sales Projection Cardiovascular Analgesics Vitamins Anti Infective 0% 5% 10% 15% 20% 25% 30% 35%
  • 23. Expenses for Registration of Pharmaceutical Company or Drug Product • Expense Head : • Registration of Pharmaceutical Company: • 10- 15 Lacs • Registration of Pharmaceutical product: • 30-45 Lacs • Agents basis : 40-45 Lacs depending upon the type of the Product to be registered
  • 24. References • Financial Express Dhaka : • Economic Times • Union of Myanmar, Minisitry of Health, Department of Health, Food And Drug Administration Medipower Myanmar, Burma